Clinical trials: Heart Attack Patients
Myocardial Infarction
Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
The purpose of this study is to determine whether Allogeneic Cardiosphere-Derived Cells (CAP-1002) is safe and effective in decreasing infarct size in patients with a myocardial infarction.
- Trial name
- ALLSTAR (NCT01458405)
- Testing
- CAP-1002 Allogeneic Cardiosphere-Derived Cells
- Where
- 32 sites in United States
- Volunteers
- 135 people
- Sponsor
- Capricor Inc.
Left Ventricular Dysfunction Post Myocardial Infarction
Patient's Management Receiving Eplerenone Therapy
On a population of patients followed by an office-based cardiologist and treated with eplerenone, the objectives of the survey are: To describe the characteristics of the population treated.
- Trial name
- PERGAME (NCT01440049)
- Testing
- Prospective Observational
- Volunteers
- 160 people
- Sponsor
- Pfizer
STEMI - ST Elevation Myocardial Infarction
Semi Occlusion of the Coronary Sinus as an Adjunct to PCI in STEMI Patients, FIH Clinical Study
The present study is planned to evaluate the safety and feasibility of the Booster Balloon catheter when applied to STEMI patients.
- Trial name
- NCT05557019
- Testing
- Booster Balloon Catheter
- Where
- 2 sites in Georgia, Israel
- Volunteers
- 20 people
- Sponsor
- Intratech Medical Ltd.
Atherosclerosis, Ischemia
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)
The study is designed to determine whether vorapaxar, when added to the existing standard of care (SOC) for preventing heart attack and stroke (eg, aspirin, clopidogrel) in participants with a known history of atherosclerosis…
- Conditions
- Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident
- Trial name
- NCT00526474
- Testing
- Vorapaxar
- Volunteers
- 26,449 people
- Sponsor
- Merck Sharp & Dohme LLC
Myocardial Ischemia, Acute Coronary Syndrome
EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)
The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death, heart attack and urgent cardiac intervention…
- Trial name
- NCT00089895
- Testing
- Eptifibatide (Integrilin)
- Volunteers
- 9,406 people
- Sponsor
- Organon and Co
ST Elevation (STEMI) Myocardial Infarction
PICSO in Patients With STEMI Treated by Primary Percutaneous Coronary Intervention
A prospective multi-center study in which patients with an acute heart attack (in the left anterior descending artery) with ECG changes (ST segment elevation) receive angioplasty followed by stent placement and 90 minutes of…
- Trial name
- pRAMSES (NCT01493037)
- Testing
- PICSO (Pressure-controlled Intermittent Coronary Occlusion
- Where
- 2 sites in Netherlands
- Volunteers
- 30 people
- Sponsor
- Miracor Medical SA
Septic Shock, Acute Respiratory Distress Syndrome
CytOSorb TreatMent Of Critically Ill PatientS Registry
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based…
- Conditions
- Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
- Trial name
- COSMOS (NCT05146336)
- Testing
- CytoSorb
- Where
- 28 sites in Austria, Germany and 4 more
- Volunteers
- 3,000 people
- Sponsor
- CytoSorbents, Inc
Myocardial Infarction
Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients
Evaluation of clinical outcomes during 12 months after inclisiran initiation in patients after STEMI/non-STEMI in real-world settings in Russia.
- Trial name
- STREAMLINE (NCT07142265)
- Where
- 18 sites in Russia
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Diseases
BIOFLOW III Satellite-Italy Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). 500 subjects will be enrolled in this registry.
- Trial name
- NCT02028728
- Where
- 18 sites in Italy
- Volunteers
- 609 people
- Sponsor
- Biotronik Italia S.p.A.
Myocardial Infarction
A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack
The study is testing the effect of ziltivekimab on reducing plaque in the blood vessels of the heart, specifically aiming to manage or reduce atherosclerotic plaque.
- Trial name
- ZEPHYR (NCT07301034)
- Testing
- Ziltivekimab
- Where
- 20 sites in Austria, Denmark and 4 more
- Volunteers
- 332 people
- Sponsor
- Novo Nordisk A/S
Myocardial Infarction
the Effect of Danhong Injection on Microcirculation in the Treatment of Patients With STEMI After the PTCA Surgery.
This study focused on the effect of Danhong injection on microcirculation in the treatment of patients with STEMI(ST-elevation myocardical infarction) after the PTCA surgery.
- Trial name
- Danhong (NCT02158559)
- Testing
- Danhong Injection, Normal Saline
- Volunteers
- 180 people
- Sponsor
- Beijing Bozhiyin T&S Co., Ltd.
ST-segment Elevation Myocardial Infarction (STEMI), Cardiogenic Shock
The RECOVER IV Trial
The purpose of this study is to assess whether hemodynamic support with an Impella-based treatment strategy initiated prior to percutaneous coronary intervention (PCI) in patients with ST-Segment Elevation Myocardial Infarction…
- Trial name
- RECOVER IV (NCT05506449)
- Testing
- Impella CP®, Standard of Care
- Where
- 7 sites in United States, Denmark and 2 more
- Volunteers
- 4 people
- Sponsor
- Abiomed Inc.
ST-elevation MI, Hypothermia
Evaluation of Ultrafast Hypothermia Before Reperfusion in STEMI Patients
This study will look at the safety of treating patients with heart attack with mild hypothermia induced using a system of automated peritoneal lavage.
- Trial name
- VELOCITY (NCT01655433)
- Testing
- Velomedix APLS device, No Hypothermia Treatment
- Where
- 7 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Velomedix, Inc.
Heart Failure, Acute Myocardial Infarction
Carvedilol Vascular Efficacy Trial
Beta-blockers should be administered to all patients with heart failure stages II to IV NYHA. It should also be administered to patients with stage I after myocardial infarction.
- Trial name
- CARVEDIA (NCT01484327)
- Testing
- Carvedilol
- Where
- Greece
- Volunteers
- 415 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Homocystine; Metabolic Disorder
Effects of Homocysteine in Myocardial Infarction Patients in a Tertiary Care Hospital of Pakistan
Raised plasma Homocysteine (Hcy) was 1st proposed as a cause of vascular pathology in patients with inherited disorders of Homocysteine metabolism.leading to the hypothesis that individuals with slight to moderate elevated levels…
- Trial name
- NCT05011032
- Testing
- Homocysteine
- Where
- Pakistan
- Sponsor
- Aqua Medical Services (Pvt) Ltd
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Belgium Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT01831336
- Where
- 8 sites in Belgium
- Volunteers
- 332 people
- Sponsor
- Biotronik Belgium NV
Myocardial Infarction
A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)
Primary objective: to evaluate the procoagulant effect of TNK-tPA compared to rt-PA and streptokinase, administered to patients with AMI, by measuring the concentration of TAT at 2 hours after the start of treatment versus…
- Trial name
- NCT02182011
- Testing
- Tenecteplase, Alteplase, Streptokinase
- Volunteers
- 49 people
- Sponsor
- Boehringer Ingelheim
Myocardial Infarction
Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI
The aim of the study is to determine if single-bolus recombinant nonimmunogenic staphylokinase is effective and save thrombolytic agent in patients presenting ST-segment elevation myocardial infarction in comparison to…
- Trial name
- FRIDOM1 (NCT02301910)
- Testing
- Recombinant staphylokinase, Tenecteplase
- Where
- 17 sites in Russia
- Volunteers
- 382 people
- Sponsor
- Supergene, LLC
Diabetes Mellitus, Type 2, NSTEMI - Non-ST Segment Elevation MI
Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg
Acute Coronary Syndrome (ACS) is triggered by the rupture of an atherosclerotic plaque that results in a platelet aggregation reaction in the coronary artery.
- Conditions
- Diabetes Mellitus, Type 2, NSTEMI - Non-ST Segment Elevation MI, Coronary Angioplasty
- Trial name
- IDASCOP 1 (NCT03329261)
- Testing
- Clopidogrel
- Where
- Tunisia
- Volunteers
- 167 people
- Sponsor
- Laboratoires Teriak
Nonfatal Myocardial Infarction, Coronary Death
Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Heart Disease Death
The purpose of this study is to estimate the risk of myocardial infarction (MI)/coronary death associated with use of monotherapy low dose ASA (single antiplatelet) as well as concomitant use of monotherapy low dose ASA and…
- Trial name
- NCT01360073
- Where
- 2 sites in Spain, Sweden
- Volunteers
- 42,542 people
- Sponsor
- AstraZeneca